Clavulanate Potassium
FDA-approved product (tablet, oral).
- Registered studies
- 50+
- Lab records
- 28
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Infection
- Infectious otitis media
- Otitis media
- Pneumonia
- Respiratory tract infectious disorder
- Sinusitis
- Soft Tissue Infections
- Urinary tract infection
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Combinations of penicillins, incl. beta-lactamase inhibitors
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01CR02
Repurposing investigation
Clavulanate Potassium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA4.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli74.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae73.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis39.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
- MRSA: measured active in 1 of 8 lab records
- E. coli: measured active in 9 of 16 lab records
- K. pneumoniae: measured active in 4 of 4 lab records
Show the 28 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Clavulanate Potassium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Preschool Wheeze: Inflammation/Infection Guided Management
NCT02517099 · start 2015-06-05
Registered record
- Registry ID
- NCT02517099
- Conditions
- Asthma
- Interventions
- Beclometasone; Co-amoxiclav; Azithromycin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2015-06-05
- Completion
- 2018-08-17
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAsthmaInterventionBeclometasone; Co-amoxiclav; AzithromycinPhasePhase 2Registry statusCompletedEffect of Vitamin D on Drug Resistant Helicobacter Pylori (HP) Eradication Study
NCT03142620 · start 2015-03
Registered record
- Registry ID
- NCT03142620
- Conditions
- H. Pylori Infection
- Interventions
- Esomeprazole; Amoxicillin-Potassium Clavulanate Combination; Clarithromycin; Vitamin D3
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2015-03
- Completion
- 2017-12
- Enrolment
- 96
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionH. Pylori InfectionInterventionEsomeprazole; Amoxicillin-Potassium Clavulanate Combination; Clarithromycin; Vitamin D3PhasePhase 3Registry statusUnknownTrial on the Ideal Duration of Oral Antibiotics in Children With Pneumonia
NCT02258763 · start 2014-11
Registered record
- Registry ID
- NCT02258763
- Conditions
- Pneumonia
- Interventions
- Amoxicillin-Potassium Clavulanate Combination; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2014-11
- Completion
- 2018-10
- Enrolment
- 19
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPneumoniaInterventionAmoxicillin-Potassium Clavulanate Combination; PlaceboPhasePhase 4Registry statusCompletedPhase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis
NCT02349841 · start 2014-09
Registered record
- Registry ID
- NCT02349841
- Conditions
- Pulmonary Tuberculosis
- Interventions
- Meropenem; Faropenem; Amoxycillin/clavulanic acid; Rifafour e275
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2014-09
- Completion
- 2014-12
- Enrolment
- 46
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary TuberculosisInterventionMeropenem; Faropenem; Amoxycillin/clavulanic acid; Rifafour e275PhasePhase 2Registry statusCompletedLevofloxacin in Bacterial Rhinosinussitis
NCT02712502 · start 2014-09
Registered record
- Registry ID
- NCT02712502
- Conditions
- Rhinosinusitis
- Interventions
- Levofloxacin; Amoxicillin-Potassium Clavulanate Combination
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2014-09
- Completion
- 2014-12
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRhinosinusitisInterventionLevofloxacin; Amoxicillin-Potassium Clavulanate CombinationPhaseNot recordedRegistry statusCompletedPhase I Study of Safety and Immunogenicity of ADU-623
NCT01967758 · start 2014-01-08
Registered record
- Registry ID
- NCT01967758
- Conditions
- Astrocytic Tumors; Glioblastoma Multiforme; Anaplastic Astrocytoma; Brain Tumor
- Interventions
- Cohort 1; Cohort 2; Cohort 3; Antibiotics
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-01-08
- Completion
- 2018-08-15
- Enrolment
- 11
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAstrocytic Tumors; Glioblastoma Multiforme; Anaplastic Astrocytoma; Brain TumorInterventionCohort 1; Cohort 2; Cohort 3; AntibioticsPhasePhase 1Registry statusCompletedA New Antibiotic Prophylaxis Regimen to Prevent Bacteremia Following Dental Procedures
NCT02115776 · start 2014-01
Registered record
- Registry ID
- NCT02115776
- Conditions
- Bacteremia
- Interventions
- Amoxicillin-Potassium Clavulanate; Amoxicillin; Chlorhexidine
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2014-01
- Completion
- 2015-05
- Enrolment
- 266
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBacteremiaInterventionAmoxicillin-Potassium Clavulanate; Amoxicillin; ChlorhexidinePhaseNot applicableRegistry statusCompletedDuration of Antibiotic Therapy as Part of Maximal Medical Therapy for Chronic Rhinosinusitis
NCT01825408 · start 2013-02
Registered record
- Registry ID
- NCT01825408
- Conditions
- Sinusitis
- Interventions
- Doxycycline; Azithromycin; Augmentin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2013-02
- Completion
- 2014-06
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSinusitisInterventionDoxycycline; Azithromycin; AugmentinPhasePhase 4Registry statusCompletedProphylactic Antibiotics After Functional Endoscopic Sinus Surgery: a Randomized, Double-blind Placebo Controlled Trial
NCT01919411 · start 2013-02
Registered record
- Registry ID
- NCT01919411
- Conditions
- Sinusitis
- Interventions
- Amoxicillin-Potassium Clavulanate; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2013-02
- Completion
- 2018-09
- Enrolment
- 134
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSinusitisInterventionAmoxicillin-Potassium Clavulanate; PlaceboPhasePhase 4Registry statusCompletedInitial Antibiotics and Delayed Appendectomy for Acute Appendicitis
NCT01697059 · start 2012-09
Registered record
- Registry ID
- NCT01697059
- Conditions
- Acute Appendicitis
- Interventions
- Piperacillin + Amoxicillin
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2012-09
- Completion
- 2015-05
- Enrolment
- 73
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute AppendicitisInterventionPiperacillin + AmoxicillinPhaseNot applicableRegistry statusCompletedEfficacy of Short-Course Antimicrobial Treatment for Children With Acute Otitis Media and Impact on Resistance
NCT01511107 · start 2012-01
Registered record
- Registry ID
- NCT01511107
- Conditions
- Acute Otitis Media
- Interventions
- Amoxicillin-Clavulanate, 10 days; Amoxicillin-Clavulanate, 5 days
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2012-01
- Completion
- 2015-10
- Enrolment
- 520
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Otitis MediaInterventionAmoxicillin-Clavulanate, 10 days; Amoxicillin-Clavulanate, 5 daysPhasePhase 2Registry statusTerminatedA Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia
NCT01110421 · start 2010-12
Registered record
- Registry ID
- NCT01110421
- Conditions
- Pneumonia, Bacterial; Community-Acquired Infections; Nosocomial Infection; Pneumonia, Ventilator-Associated
- Interventions
- Cefepime placebo; Cefepime; Doripenem; Doripenem placebo; Amoxicillin/clavulanate potassium
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2010-12
- Completion
- 2012-03
- Enrolment
- 7
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPneumonia, Bacterial; Community-Acquired Infections; Nosocomial Infection; Pneumonia, Ventilator-AssociatedInterventionCefepime placebo; Cefepime; Doripenem; Doripenem placebo +1 morePhasePhase 3Registry statusTerminatedShort (5 Days) Versus Long (14 Days) Duration of Antimicrobial Therapy for Acute Bacterial Sinusitis in Children
NCT01166945 · start 2010-11
Registered record
- Registry ID
- NCT01166945
- Conditions
- Sinusitis
- Interventions
- Amoxicillin-Potassium Clavulanate Combination; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2010-11
- Completion
- 2016-02
- Enrolment
- 98
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSinusitisInterventionAmoxicillin-Potassium Clavulanate Combination; PlaceboPhaseNot applicableRegistry statusCompletedMonotherapy Versus Bitherapy in Non-severe Hospitalized Community-acquired Pneumonia
NCT00818610 · start 2009-01
Registered record
- Registry ID
- NCT00818610
- Conditions
- Community-acquired Pneumonia
- Interventions
- Beta lactam (amoxicillin / clav. acid OR cefuroxime); Beta-lactam (amoxicillin / clav. acid OR cefuroxime) AND macrolide (clarithromycin)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2009-01
- Completion
- 2013-04
- Enrolment
- 601
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCommunity-acquired PneumoniaInterventionBeta lactam (amoxicillin / clav. acid OR cefuroxime); Beta-lactam (amoxicillin / clav. acid OR cefuroxime) AND macrolide (clarithromycin)PhasePhase 4Registry statusCompletedZmax Compared to Augmentin in Sinusitis
NCT00367120 · start 2006-06
Registered record
- Registry ID
- NCT00367120
- Conditions
- Sinusitis
- Interventions
- Azithromycin Extended Release; Amoxicillin/Clavulanate
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2006-06
- Completion
- 2007-02
- Enrolment
- 762
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSinusitisInterventionAzithromycin Extended Release; Amoxicillin/ClavulanatePhasePhase 4Registry statusCompleted